Effect of moderate restriction diet in treatment of non-alcoholic fatty liver disease

Not Applicable

Conditions: on-alcoholic fatty liver disease.
Fatty (change of) liver, not elsewhere classified
K76.0

Registration Number: IRCT20210119050086N1

Lead Sponsor: Tehran University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Complete

Sex: All

Target Recruitment: 52

Inclusion Criteria

Body mass index 18.5-25 kg/m2
Age range 18-65 years
Patients with non-alcoholic fatty liver disease

Exclusion Criteria

Alcohol consumption
Pregnancy or breastfeeding
Suffering from other liver diseases
Consuming corticosteroids during the last three months
Drugs or tobacco use
Follow a weight loss diet during the last three months

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Steatosis. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Fibro-scan.;Liver enzyme (ALT, AST and GGT). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.

Secondary Outcome Measures

Name	Time	Method
ipid profile (TG, Total cholesterol, LDL-c and LDH-c). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Glycemic index (FBS, FBI, HOMA-IR and QUICKI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Blood sample.;Weight. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Scales.;Waist circumference. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Tape meter.;Body mass index (BMI). Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Formula (weight (kilograms) divided by the squared height (meters)).;Fibrosis. Timepoint: Beginning the intervention and 12 weeks later at the end of the intervention. Method of measurement: Fibro-scan.